CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Clinical trial NCT02955290 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02955290
Sponsor: Roswell Park Cancer Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Head and Neck Squamous Cell Carcinoma Lung Non-Small Cell Carcinoma Metastatic Lung Non-Small Cell Carcinoma PD-L1 Positive Recurrent Head and Neck Squamous Cell Carcinoma Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 Stage III Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 Stage IIIB Lung Cancer AJCC v8 Stage IIIC Lung Cancer AJCC v8 Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 Stage IV Lung Cancer AJCC v8

Start date: 2016-12-22
Primary completion: 2026-11-25
Enrollment: 51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.